Loading...
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions
Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of mult...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4532715/ https://ncbi.nlm.nih.gov/pubmed/26187774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0440-8 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|